|
 |
PrografThis page contains recent news articles, when available, and an overview of Prograf but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Prograf (when available) Tacrolimus, a macrolide immunosuppressant produced by Streptomyces tsukubaensis, is an immunosuppressive agent indicated for the treatment of patients receiving kidney and/or liver transplants. Tacrolimus has been demonstrated to suppress humoral immunity and, to a greater extent, cell-mediated reactions such as allograft rejection, delayed type hypersensitivity, collagen- induced arthritis, experimental allergic encephalomyelitis, and graft versus host disease. It has similar immunosuppressive properties to cyclosporine, but is much more potent in equal volumes. Tacrolimus is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver or kidney transplants. Used in a topical preparation in the treatment of severe atopic dermatitis, also used after bone marrow transplants and for severe refractory uveitis. Mechanism Of Action: Tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of Tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, Tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. News Articles on Tacrolimus Astellas Wins Approval for Overactive Bladder Treatment in China - Dec 22, 2009 In 2008, Astellas China's revenues were about $100 million, led by its flagship product, Prograf, an immunosuppressant used to prevent rejection of ... Seeking Alpha (blog) LifeCycle Pharma submits Phase 3 Protocol for LCP-Tacro to FDA - Dec 23, 2009 De novo kidney transplant candidates areAexpected to be randomized to receive either LCP-Tacro or Prograf following their kidney transplantation, ... Trading Markets (press release) LFP-Geschäft soll weiter wachsen - Dec 17, 2009 ...(dmnet) Insbesondere im dritten Quartal habe das Unternehmen gute Verkaufszahlen bei Rollensystemen aus der Image Prograf-Serie erreicht. ... Druck-Medien.net ä¸åŒ–æ?¶æ?å…?疫抑制劑商機 - Dec 29, 2009 ...塔克莫å?¸è—¥ç‰©åŽŸå» 為日本阿斯特拉斯（Astella Pharma Prograf），該藥物為全ç?ƒæœ€ä¸»è¦?的器官移æ¤?抗排斥用藥，已行銷全ç?ƒ80多個國家和地å?€ï¼ŒåŽ»å¹´éŠ·å”®é¡?716億元，今年åˆ?ä¼° ... 中時電子報 Hikma 3Q Sales Slow; Western JV Within Months - Nov 12, 2009 Advagraf is a newer version of a drug called Prograf. Noble analyst Stefan Hamill said in a research note the licensing deal is significant because he ... Wall Street Journal Astellas Pharma set to launch Prograf in India, works on marketing strategy - Nov 12, 2009 Prograf, the world's best-selling drug used to stop transplanted organs from being rejected, is planned to be commercialised in the country by the first ... pharmabiz.com Astellas Cuts Annual Profit Outlook on Yen, Charges - Nov 4, 2009 ...“Given the current situation of Prograf sales, the company probably can't help but be conservative about its forecasts.â€? Astellas projects research and ... Bloomberg Astellas counts the cost of Prograf generic - Nov 6, 2009 Sales edged up 0.3% to 494.64 billion yen, driven by Prograf (tacrolimus). However sales of the drug were down 1.3% to 103.00 billion yen, as Novartis unit ... Pharma Times New Canon showroom tipped as UK's largest - Nov 12, 2009 The new showroom will display all Canon's large-format Image PROGRAF line-up, as well as the C1+, a new light-production printer. There is also a boardroom ... CRN - UK Astellas wins Japanese approval for additional indication of Prograf - Oct 19, 2009 Prograf has already been approved for 'myasthenia gravis in a case where the effect of steroids is insufficient or administration of steroids is difficult ... Trading Markets (press release) India is hot for mid-size pharma, too - Nov 6, 2009 Japan's Astellas Pharma is now recruiting sales execs for the launch of its first product in India, its flagship transplant drug Prograf, which is running ... FiercePharma LifeCycle Pharma Announces Result for the First Nine Months of 2009 and ... - Nov 12, 2009 ...phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf(R). ... Benzinga Astellas Pharma Inc. - SWOT Analysis - research report released - Oct 26, 2009 The increase in revenues during FY2008 was mainly due to the expanded global sales of Prograf and Vesicare. The operating profit of the company was JPY275 ... PR-Inside.com (Pressemitteilung) LEAD: Tokyo stocks fall on losses in financial, resource shares - Oct 27, 2009 Barclays Capital downgraded the drugmaker's investment rating on its loss in market share for the immune system drug Prograf. ... istockAnalyst.com (press release) Commercial Insight - Solid organ transplantation - The impact of new biologics ... - Oct 23, 2009 However, the combined sales of Astellas´s tacrolimus franchise (Prograf and once-daily Advagraf) will dominate the immunosuppressant market over the next ... PR-Inside.com (Pressemitteilung) Astellas licenses Medivation's prostate cancer candidate - Oct 28, 2009 ...by analysts at Barclays Capital to "underweight" from "equal weight", on the basis of generic competition to its transplant drug Prograf (tacrolimus). ... Pharma Times India is growth tonic for mid-tier global pharma - Nov 1, 2009 Astellas is now recruiting sales executives to launch its first product in India, its $2 billion flagship brand Prograf, used to prevent rejection in organ ... Rediff Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide - Nov 9, 2009 Astellas has discovered an over-active bladder (OAB) medication, Vesicare® and an immunosuppressive agent, Prograf® (tacrolimus), which have enabled them to ... SYS-CON Media (press release) PRESS RELEASE: Novartis Delivers Strong New -3- - Oct 21, 2009 ...consecutive quarter in 2009 of year-on-year growth thanks to new product launches, including a first-to-market launch of generic tacrolimus (Prograf®). ... Capital.gr (press release) Novartis T3: performance hétérogène divisions non pharma - Sandoz en bonne voie - Oct 21, 2009 ...pour le deuxième trimestre d'affilée, une croissance, comparé aux mêmes trimestres de 2008, grâce au lancement de nouveaux produits, comprenant Prograf, ... Romandie.com æ—¥ ì œë„¤ë¦ ì‹œìž¥ '외ìž?사 진출러시' - Nov 2, 2009 ...ìš°ì„ ë‚´ë…„ì—? '노보믹스'(NovoMix, insulin aspart), 'ì•…í† ë„¬'(Actonel, risedronate), 'ì„¸ë ˆë²¤íŠ¸'(Serevent, salmeterol), '프로그ëž?'(Prograf, tacrolimus)ì?˜ 특허가 ... 디지틀보사 Literatüre geçti ama ilacını alamıyor - Oct 26, 2009 Biri (Rapamone) 876 diÄŸeri (Prograf) 176 liraâ€? dedi. Nakil ekibinden Opr. Dr. Selçuk Kılınç da ilaç sorununun, ince bağırsak naklinin böbrek, ... Star Gazete Literatüre geçti ama ilaç engelini geçemedi - Oct 26, 2009 Biri (Rapamone) 876, diÄŸeri (Prograf) 176 lira. Devlet bunu karşılamıyor. EÅŸim SSK emeklisi. Ne yapıp edip ilaçları alıyoruz, ama nereye kadar? ... Milliyet Gel de yaÅŸa - Oct 25, 2009 Biri (Rapamone) 876 diÄŸeri (prograf) 176 lira. Ancak devlet bunu karşılamıyor. Ä°nce barsak nakilli yaÅŸayan ilk ve tek hastayım ama bu ÅŸartlarda gel de yaÅŸa. ... Hürriyet La concentración de medios y sus implicaciones polÃticas, éticas y económicas ... - Oct 29, 2009 La empresa PROGRAF SA Adicionalmente posee participaciones minoritarias en el Diario El Comercio y en EDIMPRES controlados por el Grupo Mantilla. ... argenpress.info DJ HUGIN NEWS/Novartis verzeichnet in den ersten -6- - Oct 21, 2009 Dazu gehörte unter anderem die erste Markteinführung einer generischen Version von Tacrolimus (Prograf®). In Mittel- und Osteuropa wurden kräftige Zuwächse ... unternehmer.de Astellas Profit Rises 5.1% on Prograf, Vesicare Drugs - Aug 1, 2008 By Kanoko Matsuyama. Aug. 1 (Bloomberg) -- Astellas Pharma Inc., Japan's second- largest drugmaker, said first-quarter profit rose 5.1 percent, ... Bloomberg Astellas' Daily Prograf Moves Closer to US Approval - Mar 14, 2008 By Jason Gale. March 14 (Bloomberg) -- Astellas Pharma Inc., Japan's second-largest drugmaker, moved closer to gaining US approval for a once-daily version ... Bloomberg Astellas: US FDA seeks more data on Prograf uses - Mar 20, 2007 TOKYO, March 20 (Reuters) - Astellas Pharma Inc. (4503.T), Japan's third-largest drug maker, said on Tuesday that US authorities have said they could not ... Reuters Astellas Third-Quarter Profit Rises 13% on Prograf, Vesicare - Feb 1, 2007 By Hiroshi Suzuki. Feb. 1 (Bloomberg) -- Astellas Pharma Inc., Japan's third- largest drugmaker, reported third-quarter profit rose 13 percent on higher ... Bloomberg … Studies Demonstrate Once-Daily Modified Release Prograf(R) Formula... - May 24, 2005 SEATTLE, May 24 /PRNewswire/ -- Two studies presented today at the 6th American Transplant Congress (ATC) demonstrate the safety and efficacy of once-daily ... RedOrbit Astellas Pharma Raises Profit Target on Tax Rate, Prograf Sales - Feb 1, 2008 By Kanoko Matsuyama. Feb. 1 (Bloomberg) -- Astellas Pharma Inc., Japan's second- largest drugmaker, raised its full-year profit forecast by 33 percent on ... Bloomberg Astellas once-daily Prograf gets EU recommendation - Feb 25, 2007 TOKYO, Feb 26 (Reuters) - Astellas Pharma Inc. (4503.T), Japan's third-largest drug maker, said on Monday a committee of the European Medicines Agency had ... Reuters UK Astellas Receives FDA Approval of Prograf(R) (Tacrolimus) for Use in ... - Mar 31, 2006 DEERFIELD, Ill., March 31 /PRNewswire/ -- The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf as an ... RedOrbit Astellas: US not ready to approve transplant drug - May 7, 2008 Astellas is keen to gain approval for Advagraf, a modified release version of transplant drug Prograf, which brings in some $2 billion in annual sales but ... Reuters … Once-a-Day Prograf MR(TM) (Modified Release) and Twice-Daily Progra... - Jul 26, 2006 BOSTON, July 26 /PRNewswire/ -- Study results presented today at the World Transplant Congress (WTC) demonstrated that investigational drug, ... RedOrbit Astellas gets EU go for once-daily transplant drug - Apr 27, 2007 The new formulation is a modified release version of Prograf, which is used to prevent organ rejection and is currently given twice a day. ... Reuters LifeCycle Pharma starts head-to-head study of LCP-Tacro vs Astellas' ... - Sep 5, 2007 Advagraf, which is once-a-day version of Astellas' Prograf, is used in renal transplants in Germany and the UK. The clinical trial will enrol 24 healthy ... Forbes Prograf gets FDA OK for heart transplant care.(Brief article) - Apr 3, 2006 The US Food and Drug Administration says it has approved Japanese drugmaker Astellas Pharma's immunosuppressant Prograf (tacrolimus hydrate) for the ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Astellas wins Japan approval for new transplant drug - Jul 17, 2008 Prograf brings in some $2 billion in annual sales but lost US patent protection earlier this year. The US Food and Drug Administration declined in January ... Reuters Astellas posts strong Q1, trims European operations - Aug 1, 2007 Sales of Prograf and Advagraf, used to prevent organ rejection in ... The US patent on Astellas' twice-daily version of Prograf runs out in 2008, ... Reuters … Once-a-Day Prograf MR(TM) (Modified Release) And Twice-Daily Prograf... - Jul 27, 2006 Study results presented today at the World Transplant Congress (WTC) demonstrated that investigational drug, once-daily Prograf MR(TM) (Modified Release) ... Medical News Today - Medical News Today (press release) Nikkei down 1.7 pct as exporters, property firms hit - Apr 9, 2008 T: Quote, Profile, Research) fell 3.5 percent to 4150 yen, one day after it lost US patent protection on transplant drug Prograf amid worries that its ... Reuters UK Astellas Bets on New Prograf Drug to Thwart Generics - Aug 23, 2007 By Kanoko Matsuyama and Yuki Hagiwara. Aug. 23 (Bloomberg) -- Astellas Pharma Inc., Japan's second-largest drugmaker, is counting on a new formulation of ... Bloomberg … Obtains Additional Approval for Its Immunosuppressant Drug Prograf - Apr 11, 2005 Prograf capsules is now available for the treatment of rheumatoid arthritis ... Released in June 1993, Prograf has been widely used for the prophylaxis of ... japancorp.net Astellas faces FDA delay on reformulated Prograf - Jan 23, 2007 The FDA has issued a nonapprovable letter to Japan's Astellas Pharma for a new formulation of its drug Prograf for heart transplant patients. ... FierceBiotech … Release: Astellas Receives FDA Approval of Prograf(R) (Tacrolimus)... - Mar 31, 2006 Astellas Receives FDA Approval of Prograf(R) (Tacrolimus) for Use in Heart Transplant Recipients. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Lifecycle Pharma posts positive data for organ rejection treatment … - Mar 3, 2008 ...'The results are a very important milestone for LCP and demonstrate LCP-Tacro's potential advantages over (competing treatment) Prograf,' Lifecycle Pharma's ... Forbes International Approvals: Follistim, Tracleer, Prograf - Apr 18, 2005 April 18, 2005 — The Japanese Ministry of Health, Labor, and Welfare has approved use of recombinant follicle-stimulating hormone injection for controlled ... Medscape Article: Astellas Pharma US receives FDA approval of Prograf for use... - Apr 17, 2006 Astellas Pharma US receives FDA approval of Prograf for use in heart transplant recipients.(United States)(Food and Drug Administration)(Brief article) ... Pay-Per-View - Transplant News - HighBeam Research Pfizer, Astellas settle Lipitor sales disagreement - Jan 26, 2007 Astellas shares gained ground on Friday, closing up 1.4 percent at 5120 yen, but are still 4 percent lower than levels prior to the Prograf news. ... Reuters Astellas Moves Closer to Gaining FDA Approval for Daily Prograf - Mar 14, 2008 By Jason Gale. March 14 (Bloomberg) -- Astellas Pharma Inc., Japan's second-largest drugmaker, moved closer to gaining US approval for a once-daily version ... Bloomberg Astellas Pharma US receives FDA approval of Prograf for use in heart ... - Apr 17, 2006 Astellas Pharma US receives FDA approval of Prograf for use in heart transplant recipients. Astellas Pharma US, Inc., Deerfield, IL, has received approval ... $9.94 - Transplant News - Alacra Store Day 1, Part 1: On the Run - May 18, 2005 These two machines come with software that may well make the two Prograf printers the ... The hard costs--consumables--for the Prograf line vary with the ... What They Think Lifecycle Pharma says transplant treatment successful in clinical... - Nov 7, 2007 ...to demonstrate LCP-Tacro's superiority to both Advagraf and (competing treatment) Prograf,' said Lifecycle Pharma chief executive Flemming Orskov. Forbes … : Once-Daily MR (Modified Release) Prograf(R) Formulation Shown to ... - Jul 26, 2006 Once-Daily MR (Modified Release) Prograf(R) Formulation Shown to Have Equivalent Efficacy and Safety to Twice-Daily Prograf(R) or Neoral(R) in Kidney ... Pay-Per-View - PR Newswire Europe - HighBeam Research Astellas Shares Rise to 2008 High on Profit Outlook - Aug 4, 2008 ...``Development of a generic version of Prograf has been delayed.'' Nakazawa rates Astellas ``outperform.'' The drugmaker expects net income of 159 billion ... Bloomberg Astellas First-Half Profit Jumps 47% on Prograf Sales - Nov 6, 2007 By Kanoko Matsuyama. Nov. 6 (Bloomberg) -- Astellas Pharma Inc., Japan's second- largest drugmaker, had a 47 percent jump in first-half profit, ... Bloomberg Senior Program .Senior Prograf . - May 1, 2005 Banner Bonk Is seeking Retail Branch Manager for our Kennewick Branch. This position will load a retail branch lo ensure exceptional customer service, ... Tri City Herald - Google News Archive … : Phase III Study Demonstrates Once-a-Day Prograf MR(TM) (Modified ... - Jul 26, 2006 Phase III Study Demonstrates Once-a-Day Prograf MR(TM) (Modified Release) and Twice-Daily Prograf(R) Are as Effective as Neoral(R) in Kidney Transplant ... Pay-Per-View - PR Newswire - HighBeam Research LifeCycle Pharma Announces Positive Topline Results From Phase II … - Jul 9, 2008 Pharmacokinetic assessment was performed on Day 7 (Prograf®) and Day 14 & 21 (LCP-Tacro). On Day 22, patients were offered to enroll in the 52-week ... Medical News Today - Medical News Today (press release) Astellas' Prograf approved for rheumatoid arthritis.(Astellas... - Apr 18, 2005 Astellas Pharma has received Japanese approval for its immunosuppressant Prograf (tacrolimus hydrate) in rheumatoid arthritis. The 5mg and 10mg capsules ... $4.95 - Pharma Marketletter - ECNext Press Release: FDA approves Prograf to prevent rejection of heart … - Mar 31, 2006 FDA approves Prograf to prevent rejection of heart transplant. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Order Prograf Without Prescription - Jul 16, 2007 The following is a partial list of North American universities that offer a Order Prograf Without Prescription in pharmacology or in related disciplines. ... Sokwanele FDA CAPSULES - Apr 11, 2006 PROGRAF APPROVED TO PREVENT REJECTION OF HEART TRANSPLANT. Prograf, a drug that suppresses the body's immune system to help prevent organ rejection in heart ... Pay-Per-View - Newsday - ProQuest Archiver Prograf COD - Aug 2, 2007 ...are typically produced by pharmaceutical companies may do a number of things:[2] * Carefully research the demand for their potential Prograf COD product ... Sokwanele Astellas Pharma's Prograf receives add'l indication for RA. - Apr 25, 2005 Prograf is an Astellas product with active ingredient tacrolimus approved as an immunosuppressant. The company has now received approval for the additional ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Prograf Digital Service Expands Field Service Solutions - Jul 23, 2008 COVINGTON, KY – JULY 22, 2008 – Prograf Digital Service, a leading provider of exceptional service experiences, printing equipment and supplies, ... What They Think Discount Prograf Without Prescription - Sep 8, 2007 ...and they enforce standards set by the European Discount Prograf Without Prescription the main body that regulates pharmaceuticals Discount Prograf Without ... Sokwanele Transplant Medicine; US FDA approves Prograf to prevent rejection of ... - May 3, 2006 2006 MAY 3 - (NewsRx.com) -- The US Food and Drug Administration (FDA) approved Prograf (tacrolimus), a drug that suppresses the body's immune reaction, ... Pay-Per-View - Immunotherapy Weekly - Factiva, from Dow Jones LifeCycle Pharma Moves LCP-Tacroâ„¢ into Clinical Phase 3 - Dec 29, 2008 Management of tacrolimus levels is complicated by the low bioavailability of Prograf®, its variable absorption and interaction with food and other drugs. ... Genetic Engineering News - Genetic Engineering News (press release) Order Prograf COD - Dec 10, 2007 This development phase can take up to 6 years the new medicine Order Prograf COD other companies from producing that medicine for a certain allocation of ... Sokwanele Discount Prograf Online - Jul 10, 2007 ...field of medication is a vital concern to medicine, but also has strong economical and political implications. To protect the consumer and prevent abuse, ... Sokwanele Generic Prograf - May 12, 2007 Molecular and Generic Prograf study of mind, brain and drugs. * Neuropharmacology - The Molecular and Behavior study of chemicals requires intimate ... Sokwanele Prograf 240 Pills X 1 Mg - Jun 9, 2007 United States, the Food and Drug Administration and they enforce standards set by the federal Prescription Drug Marketing Act (PDMA) * Psychopharmacology ... Sokwanele Transplant Medicine; US FDA approves Prograf to prevent rejection of ... - May 5, 2006 2006 MAY 5 - (NewsRx.com) -- The US Food and Drug Administration (FDA) approved Prograf (tacrolimus), a drug that suppresses the body's immune reaction, ... Pay-Per-View - Drug Week - Factiva, from Dow Jones TAKEDA, FUJISAWA ONLY BIG JAPAN DRUGMAKERS TO POST … - Feb 1, 2005 Fujisawa's revenue, meanwhile, edged up 2 per cent to 323 billion yen, led by solid sales of its Prograf immunosuppressant. Sankyo Co. ... $4.95 - AsiaPulse News - ECNext Prograf Digital Service Launches National Field Service Network - Oct 10, 2008 Covington, KY – OCTOBER 8, 2008 – Prograf Digital Service (PDS), a leading provider of exceptional service experiences, printing equipment and supplies, ... What They Think Press Release: Prograf Now Approved for Prophylaxis Use in Heart … - Apr 21, 2006 Prograf Now Approved for Prophylaxis Use in Heart Transplantation Across Europe. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Astellas Pharma's Immunosuppressant Prograf Now Available in Europe. - Apr 25, 2006 Tokyo, Japan, Apr 24, 2006 - (JCN) - Astellas Pharma recently announced the European Commission's approval of the Company's proprietary immunosuppressant ... Free with registration - JCNN News Summaries - AccessMyLibrary.com Canon's image Prograf Large Format Printers Honored By Bertl, Inc. - Jun 11, 2008 Canon USA, Inc., a leading provider of office imaging systems, inkjet technology and digital photography equipment, today announced its imagePROGRAF iPF710, ... webwire.com … helps prevent heart transplant rejection.(Prograf from Astellas... - Jul 1, 2006 A new drug that suppresses the body's immune reaction for the prevention of graft rejection in heart transplant recipients has been approved by the FDA. ... $4.95 - FDA Consumer - ECNext … Release: Kidney Transplant Patients Treated With Prograf(R) Show... - Jul 25, 2006 Kidney Transplant Patients Treated With Prograf(R) Show Better Renal and Lipid Responses Compared With Neoral(R). from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research International Approvals: Omnitrope, Prograf, Cetrotide - May 1, 2006 May 1, 2006 — The European Commission has approved a generic formulation of somatropin for use as long-term replacement therapy in children and adults, ... Medscape TradeName : Pangraf, Vingraf, Prograf, Protopic, Tacromus - Dec 31, 2008 Why it is prescribed (Indications) : Tacrolimus is used to prevent rejection of Kidney, Heart and Liver Transplanted organ . It is also used for treatment ... MedIndia Hepatitis C Infection Raises Diabetes Risk After Liver Transplants - Jan 8, 2007 8 -- Liver transplant recipients who are hepatitis C-virus (HCV) positive and receive Prograf (tacrolimus) as part of their immunosuppressant regimen are at ... MedPage Today LifeCycle Pharma Initiates Phase II Clinical Trial for LCP-Tacro, an ... - Dec 3, 2007 Management of tacrolimus levels is complicated by the low bioavailability of Prograf, its variable absorption and interaction with food and other drugs. ... Genetic Engineering News - Genetic Engineering News (press release) Positive kidney transplant data for Atellas' Prograf. - Jul 31, 2006 Positive kidney transplant data for Atellas' Prograf. Japanese drug major Astellas has reported new data showing that after only six months post-conversion ... $9.94 - Pharma Marketletter - Alacra Store FDA APPROVES ASTELLAS PHARMA'S PROGRAF TO TREAT HEART … - Apr 25, 2006 The US FDA has approved Japanese drugmaker Astellas Pharma's Prograf -- a drug that suppresses the body's immune response -- for the prevention of graft ... Pay-Per-View - Daily International Pharma Alert - Factiva, from Dow Jones PROGRAF APPROVED TO PREVENT HEART TRANSPLANT … - Apr 11, 2006 The FDA has approved Astellas Pharma's Prograf -- a drug that suppresses the body's immune response -- for the prevention of graft rejection in heart ... Pay-Per-View - FDAnews Drug Daily Bulletin - Factiva, from Dow Jones Once-a-Day or Twice-Daily Tacrolimus as Effective as Cyclosporine in ... - Aug 3, 2006 Prograf MR is a modified release version of the FDA-approved twice-daily ... Both formulations of Prograf also showed significantly less treatment failure ... DG News Astellas' modified Prograf Oked in Japan. - Jul 28, 2008 Astellas' modified Prograf Oked in Japan. Japanese drugmaker Astellas has received marketing approval for the immunosuppressant Graceptor (tacrolimus ... $9.94 - Pharma Marketletter - Alacra Store Japan's Astellas to market new immunosuppressive drug Advagraf in … - Jun 18, 2007 Including sales of the popular Prograf, which is the twice-a-day version of Advagraf, the Japanese drugmaker said it targets annual sales of some 190.4 bln ... ABCmoney.co.uk LifeCycle Pharma Announces Positive Phase I Clinical Results for its ... - May 31, 2007 ..."The once-daily profile and significant increase in bioavailability, compared to Prograf(R), that has been demonstrated for our LCP-Tacro product candidate ... $4.95 - PR Newswire - ECNext Cyclosporine Shows Advantage Over Tacrolimus - Jan 6, 2006 The most commonly used anti-rejection medication is tacrolimus, brand name Prograf, marketed by Astellas Pharma, although cyclosporine (Sandimmun) produced ... RedOrbit Article: Post--kidney-transplant Prograf may spur diabetes.(Clinical ... - Nov 1, 2006 Post--kidney-transplant Prograf may spur diabetes.(Clinical Rounds) ... find Skin & Allergy News articles. BOSTON -- Use of tacrolimus after kidney ... Pay-Per-View - Skin & Allergy News - HighBeam Research Infliximab Injection Side Effects from Consumer Reports Health. - Jan 4, 2007 Sandimmune), oral corticosteroids; 6-mercaptopurine (Purinethol); methotrexate (Rheumatrex), sirolimus (Rapamune), and tacrolimus (Prograf). ... consumerreports.org Japan stock market week to October 9, 2006.(forecasts and trends) - Oct 16, 2006 The company anticipates a difficult operating environment due to the patent expiration of two of its main drugs, the immunosuppressant Prograf (tacrolimus) ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Astellas Pharma US, Inc., Deerfield, IL, Aug. 31 (DDMAC).(HUMAN … - Sep 1, 2006 Moreover, the ad indicated that Prograf users exhibited a "favorable cardiovascular profile with significantly fewer Prograf-treated patients requiring ... $4.95 - Warning Letter Bulletin - ECNext Astellas in mid-stage trials of new transplant drug - Sep 12, 2007 Astellas has also developed a once-daily version of Prograf, which is currently given twice a day, and which has been approved in Europe. ... Reuters LifeCycle Pharma Announces Transplantation Programs On Track - Jan 22, 2008 Prograf® is currently marketed worldwide by Astellas Pharma as twice-a-day capsules of tacrolimus. These results are consistent with the interim results ... Medical News Today - Medical News Today (press release) LifeCycle Pharma Announces Transplantation Programs on Track - Jan 18, 2008 Prograf(R) is currently marketed worldwide by Astellas Pharma as twice-a-day capsules of tacrolimus. These results are consistent with the interim results ... Genetic Engineering News - Genetic Engineering News (press release) Long-term stability of a patient-convenient 1 mg/ml suspension of … - Mar 6, 2006 Tacrolimus (Prograf ® , FK506, Fujisawa Healthcare) is a widely used ... Tacrolimus (Prograf ® , Fujisawa, Deerfield, IL, USA) suspensions were prepared to ... Nature.com Study finds low-dose Pharma drug best after transplant - Dec 19, 2007 BOSTON (Reuters) - Small doses of Astellas Pharma Inc's Prograf did a better job at preventing rejection of a transplanted kidney than varying doses of ... Reuters Nuovi plotter Canon per professionisti - Sep 9, 2005 Canon ha annunciato l'introduzione di due nuovi sistemi di stampa a largo formato (LPF) con inchiostro a base dye: imagePrograf W8400D e image Prograf ... Punto Informatico LifeCycle Pharma Announces Positive Interim Phase II Clinical Trial … - Oct 26, 2007 Prograf([R]) is currently marketed worldwide by Astellas Pharma as twice-a-day capsules of tacrolimus. "We are pleased with the positive results of this ... $4.95 - Business Wire - ECNext Justiça determina retorno do fornecimento do Prograf - Dec 12, 2008 O juiz da VII Vara da Justiça Federal no Ceará determinou o retorno do fornecimento do remédio Prograf para o tratamento de transplantados. ... Diário do Nordeste - Diário do Nordeste (Assinatura) COMUNICADO: Prograf recibe la aprobación de uso en Europa para la … - Apr 21, 2006 TOKIO y LONDRES, April 21 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; sede: Tokio; director general y consejero delegado: Toichi Takenaka) ha ... elEconomista.es Prograf nun als Prophylaxe bei Herzverpflanzungen in Europa … - Apr 21, 2006 Tokio und London (ots/PRNewswire) - Astellas Pharma Inc. ("Astellas"; Firmensitz: Tokio; President und CEO: Toichi Takenaka) kündigte heute an, ... presseportal.de Astellas' says Advagraf represents step forward in post-transplant … - Oct 8, 2007 In terms of safety, Prof Neumayer said that Advagraf and Prograf had demonstrated similar safety profiles, but added that the rate of post-transplant ... $4.95 - Pharma Marketletter - ECNext Canon steps up presence in CAD, GIS markets - Nov 25, 2007 The Image Prograf iPF610 is able to deliver a full colour A1 print on plain ... The Image Prograf iPF710 and iPF610 replace the Image Prograf iPF700 and ... Times of Malta Tailoring Immunosuppressant Dosages for Each Liver Graft Patient - Jun 13, 2005 Immunosuppressants used in the study were Prograf and Sandimmune. ... Sixty-one percent of the group took Prograf as their primary immunosuppressive drug. ... MedPage Today Bruk av Advagraf og Prograf – risiko for feildosering - Dec 19, 2008 Forveksling av doser ved bruk av legemidlene Advagraf og Prograf har ført til alvorlige bivirkninger for pasienter. Det er viktig at helsepersonell er ... Statens legemiddelverk Продажи препаратов Prograf и Vesicare Ñ?поÑ?обÑ?твовали 52- … - Aug 1, 2007 ЯпонÑ?каÑ? фармацевтичеÑ?каÑ? компаниÑ? Astellas Pharma опубликовала 1 июлÑ? финанÑ?овый отчет за I квартал 2008 финанÑ?ового года. Прибыль компании за отчетный ... ФармацевтичеÑ?кий веÑ?тник ФинанÑ?овые новоÑ?ти архив Ð?а фоне роÑ?та продаж препаратов Progra - Feb 1, 2007 Ð’ четверг третьÑ? по величине в Японии фармацевтичеÑ?каÑ? компаниÑ? Astellas Pharma опубликовала финанÑ?овый отчет за III квартал 2007 финанÑ?ового года. ... K2Kapital Press Release: Sirolimus Reduces the Risk of Cancer in Kidney … - Feb 6, 2006 Article: Kidney Transplant Patients Treated With Prograf(R) ... ... Article: Once-Daily MR (Modified Release) Prograf(R) Formulation Shown to ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research Corte Suprema declara inadmisible recurso en arista de caso MOP Gate - Feb 20, 2008 ...de Santiago que el 4 de diciembre pasado condenó a los dos acusados a las penas anteriormente indicadas en el proceso también conocido por MOP-Prograf. ... Crónica Concepción LifeCycle Pharma Announces Positive Phase I Clinical Results for its ... - May 30, 2007 ..."The once-daily profile and significant increase in bioavailability, compared to Prograf(R), that has been demonstrated for our LCP-Tacro product candidate ... Genetic Engineering News - Genetic Engineering News (press release) Canon realizó su encuentro de fotografÃa profesional - Nov 29, 2007 Además, durante el encuentro, los profesionales pudieron observar los equipos de impresión, entre los que se encontraban image PROGRAF IPF 5000/17 que ... CanalAR Lifecycle Pharma klar til fase III med transplantationsmiddel - Nov 27, 2008 300 stabile, nyretransplanterede patienter i andet halvÃ¥r af 2008, hvor patienterne skifter fra Prograf to gange dagligt til LCP-Tacro én gange dagligt med ... UgensErhverv MOP suma procesados - Mar 29, 2006 D'Hainaut GarcÃa, asesoraba, entre 2001 y 2002, al ex ministro ya la empresa Prograf Impresores limitada. Por otra parte, López Mezquita, dueño de esta ... Diario Renacer de Angol Press Release: Long Term Sirolimus Data Brings Hope for Kidney … - Feb 1, 2005 Article: Primary Therapy with Prograf(R) in Combination with Adjunctive ... ... Article: Kidney Transplant Patients Treated With Prograf(R) ... ... Pay-Per-View - PR Newswire - HighBeam Research Shigeo Nakanishi und Iwao Yamanaka (Japan) - Aug 18, 2008 Das Medikament, welches in über 70 Ländern als Prograf vermarktet wird, ... Die beeindruckende Bilanz von Prograf kann sich sehen lassen: Seit Prograf 1994 ... European Patent Office Article: Long Term Sirolimus Data Brings Hope for Kidney Transplant … - Jan 31, 2005 Article: Primary Therapy with Prograf(R) in Combination with Adjunctive ... ... Article: Kidney Transplant Patients Treated With Prograf(R) ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research Astellas' fiscal 2007 sales increase 5.6%. - Jun 2, 2008 Domestic revenues inched up 0.7% to 505.5 billion yen, with Prograf sales up ... The US patent on Astellas' top earner, Prograf, expires in fiscal 2008 but ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Aspreva and Roche announce preliminary results for … - Jun 27, 2007 Article: Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) . ... Article: Primary Therapy with Prograf(R) in Combination with Adjunctive . ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Prograf is also known by the following brand names and/or synonymsFK 506; FK-506; FK5; K506; Prograf; Protopic; Tacarolimus; Tacrolimus Drug Category: Prograf is categorized under the following by the FDA: Immunosuppressive Agents; ATC:D11AX14; ATC:L04AA05 Dosage Forms: CAPSULE; OINTMENT; SOLUTION Absorption: Generally incomplete with absolute bioavailability of 17-22% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3- [2-(4-hydroxy-3-methoxycyclohexyl) -1-methylethenyl]-14, 16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15, 19-epoxy-3H-pyrido[2,1-c][1,4] oxaazacyclotricosine-1,7,20, 21(4H,23H)-tetrone, monohydrate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |